CA
ALXN

Capital Advantage’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Advantage’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,362
Closed -$361K – 118
2021
Q1 		$361K Hold
2,362
– – 0.1% 80
2020
Q4 		$372K Hold
2,362
– – 0.11% 72
2020
Q3 		$296K Hold
2,362
– – 0.1% 72
2020
Q2 		$265K Hold
2,362
– – 0.09% 73
2020
Q1 		$244K Buy
+2,362
New +$232K 0.1% 74

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Capital Advantage's ALXN Position: Q2 2021 in Review

Capital Advantage sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 2,362 shares — an estimated $361K sold.

Capital Advantage first reported a position in ALXN in Q1 2020 and held it in 5 quarters. The position peaked at $372K in Q4 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Capital Advantage reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Capital Advantage sold 2,362 Alexion Pharmaceuticals shares in Q2 2021, an estimated $361K.
  • Capital Advantage first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Capital Advantage's Alexion Pharmaceuticals position peaked at $372K in Q4 2020.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Capital Advantage's 13F filing for Q2 2021, filed 16 Aug 2021.